Skip to main content
main content, press tab to continue

Life sciences report 2022

March 10, 2022

Managing the new political risks in life sciences
Credit and Political Risk|Environmental Risks

Our 2022 report is based on interviews with a panel of nine executives representing leading life science companies and industry analysts, including pharmaceutical and biotech companies, medical devices companies, and an industry association. We asked our interviewees to speak candidly, and off the record, about the new political risks their industry is facing, and they did so. We have used their views to compile the political risk radar that opens the report.

The COVID-19 emergency has boosted public investment in life sciences to levels that may well be unprecedented, and some life sciences companies have reaped share price rewards from being at the front lines of the struggle against the pandemic.

On the other hand, political attention can create political risks. Political decisions taken in an emergency – such as weakening patent rights – may prove to have long-term detrimental consequences, some of them unanticipated. Geopolitics is adding another source of political risk. The relationships between China and the West, and Russia and the West, have become increasingly tense.

Can life sciences companies manage these new political risks? What risks will companies face if politicians seek to unwind global healthcare supply chains? What risks might arise from pandemic-related economic turmoil? What political risk perils might be lurking “under the radar?”

Please download the full report to continue reading.

Title File Type File Size
Life sciences report 2022 PDF 1.2 MB


Willis Towers Watson offers insurance-related services through its appropriately licensed and authorised companies in each country in which Willis Towers Watson operates. For further authorisation and regulatory details about our Willis Towers Watson legal entities, operating in your country, please refer to our Willis Towers Watson website. It is a regulatory requirement for us to consider our local licensing requirements.

The information given in this publication is believed to be accurate at the date of publication shown at the top of this document. This information may have subsequently changed or have been superseded and should not be relied upon to be accurate or suitable after this date.


North American Practice Leader – Life Sciences

Head of Broking and Market Engagement & Head of Credit and Political Risk for Corporates

Director of Political Risk Analytics, Financial Solutions

Contact us